Acyl sulfonamide nav1.7 inhibitors
AssigneeBristol-Myers Squibb Company
InventorsYong-Jin WU, Jason M. Guernon
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)
Claims12
A compound of formula I
- where:
- A is N(R4)(R5) or OR4;
- R1 is thiazolyl or thiadiazolyl and is substituted with 0-2 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
- and
- R2 is cyano, halo, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- R3 is cyano, halo, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- R4 is alkyl, (cycloalkyl)alkyl, or cycloalkyl, and is substituted with 0-2 substituents selected from hydroxyalkyl, alkoxyalkyl, (Ar1)alkyl, hydroxy, alkoxy, tetrahydrofuranyl, tetrahydropyranyl, hexahydrofurofuranyl, and Ar1;
- or R4 is (R6R7N)alkyl, ((R6R7N)cycloalkyl)alkyl, (((R6R7N)alkyl)cycloalkyl)alkyl, (R6R7N)cycloalkyl, ((R6R7N)alkyl)cycloalkyl, or (R6R7N) and is substituted with 0-3 halo or alkyl substituents, and with 0-1 Ar1 or (Ar1)alkyl substituents;
- or R4 is a [1-4.1-4.0-2]bridgedbicyclicamine with 0-3 halo or alkyl substituents;
- or R4 is (tetrahydrofuranyl)alkyl, (tetrahydropyranyl)alkyl, (dioxanyl)alkyl, (dioxothiopyranyl)alkyl, or (hexahydrofurofuranyl)alkyl;
- R5 is hydrogen or alkyl;
- or NR4R5 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperidinonyl, piperazinyl, or morpholinyl, and is substituted with 0-1 NR6R7 substituent and also with 0-5 halo or alkyl substituents;
- or NR4R5 taken together is a [1-4.1-4.0-2]bridgedbicyclicdiamine with 0-3 halo or alkyl substituents;
- R6 is hydrogen, alkyl, or cycloalkyl;
- R7 is hydrogen, alkyl, or cycloalkyl;
- or NR6R7 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperidinonyl, piperazinyl, or morpholinyl, and is substituted with 0-5 halo, hydroxyl, alkyl, hydroxyalkyl, or alkoxyalkyl substituents;
- or NR6R7 taken together is oxaazaspirodecanyl;
- and
- Ar1 is phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
A method for treating pain in a patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.